99% Pure Tranexamic Acid Powder for Skin Brightening

• Certification: Hala
• Assay Method: HPLC
• Application Form: Injection, Lotion, Suppository, Paste, Tablet, Capsule
• Model NO.: JT-319
• Application: Health Care Products, Medicine, Cosmetics
• State: Powder
• Transport Package: 25kgs/Drum or Carton, Inner by Aluminum Foil Bag
• Specification: 99%
• Origin: China
• HS Code: 1302199099
• Production Capacity: 1000kg/Month

Product Description

Product name	Tranexamic Acid
Appearance	White powder
CAS	1197-18-8
Test Method	HPLC
Molecular Formula	C8H15NO2
Molecular Weight	157.21
EINECS	214-818-2

Tranexamic Acid
Tranexamic acid (Tranexamic acid), also known as tranexamic acid, coagulation acid, hemostatic acid, the chemical name is trans-4-aminomethylcyclohexane formic acid, is an organic compound, the chemical formula is C8H15NO2, mainly used as a hemostatic agent.
Specification:  99%
Solubleness:Slightly soluble in water
This product can be used for:
1, prostate, urethra, lung, brain, uterus, adrenal gland, thyroid gland, liver and other organs rich in plasminogen activator trauma or surgical bleeding.
2, used as thrombolytic agents, such as tissue plasminogen activator (t-PA), streptokinase and urokinase antagonists.
3. Fibrinolytic hemorrhage due to induced abortion, early placental exfoliation, stillbirth, and amniotic fluid embolism.
4. Menorrhagia, anterior chamber hemorrhage and severe epistaxis with increased local fibrinolysis.
5. It is used to prevent or reduce bleeding after tooth extraction or oral surgery in hemophilia patients with factor VIII or factor IX deficiency.
6. In mild bleeding caused by central aneurysm rupture, such as subarachnoid hemorrhage and intracranial aneurysm hemorrhage, the use of this product is superior to other anti-fibrinolytic drugs, but the risk of cerebral edema or cerebral infarction must be paid attention to. As for severe patients with surgical indications, it can only be used as an auxiliary drug.
7, for the treatment of hereditary angioedema, can reduce the frequency and severity of attacks.
8, active bleeding in patients with hemophilia.
9. It has definite curative effect on chloasma.